Asahi Kasei bags breakthrough ADC tech in push for safer & more precise cancer therapies
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
NEJM study shows strong protection across strains
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
The license is valid for five years, effective from April 9, 2026
Subscribe To Our Newsletter & Stay Updated